Objective: The purpose of this study is to describe the pharmacokinetics of phenytoin in pediatric patients receiving fosphenytoin. Design: Retrospective, population pharmacokinetic analysis. Setting: Emergency department or PICU of a large tertiary care children’s hospital. Patients: Patients less than 19 years old who received fosphenytoin in the PICU or emergency center for treatment of seizures from January 2011 to June 2017 were included. Interventions: Population pharmacokinetic analysis was performed with NONMEM v7.3 (Icon Plc, Dublin, Ireland). Simulation was performed to determine optimal loading dose and maintenance dosing regimens. Measurements and Main Results: A total of 536 patients (55.4% male; median age, 3.4 yr [interquartile range, 0.92–8.5 yr]) met study criteria. Fosphenytoin was administered at median 15.1 mg/kg/dose (interquartile range, 6.3–20.7 mg/kg/dose). Mean serum concentrations of 17.5 ± 7.8 mg/L were at a median 4.2 hours (interquartile range, 2.5–7.8 hr) after a dose. A pharmacokinetic model with two compartments, allometrically scaled fat-free mass on all parameters, and serum creatinine and concomitant phenobarbital use on clearance had the best fit. Simulation demonstrated that a 20 mg/kg loading dose followed by 6 mg/kg/dose every 8 hours had the greatest percentage of concentrations in the 10–20 mg/L range, with reduced doses to achieve therapeutic in patients with reduced kidney function. Conclusions: A loading dose of 20 mg/kg followed by 6 mg/kg/dose every 8 hours based on fat-free mass is a reasonable empiric strategy for attainment and maintenance of therapeutic trough concentrations. Concomitant phenobarbital use may increase clearance of phenytoin and fosphenytoin dose reductions should occur in patients with reduced kidney function. Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (https://ift.tt/2gIrZ5Y). Dr. Weingarten received funding from Greenwich Pharmaceuticals. Drs. Weingarten and Riviello disclosed off-label product use in the article. The remaining authors have disclosed that they do not have any potential conflicts of interest. For information regarding this article, E-mail: bsmoffet@texaschildrens.org ©2018The Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies
from Emergency Medicine via xlomafota13 on Inoreader https://ift.tt/2MOKgO2
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Champion EMS is currently seeking a Communications Center Manager. Champion EMS is based out of Longview, Texas, serving the East Texas area...
-
from EMS via xlomafota13 on Inoreader http://ift.tt/2sbML2K
-
Remove ads BioMed Research International Validity and Reliability of the Polish Adaptation of the CHAMPS Physical Activity Questionnaire Th...
-
Abstract Objectives Emergency departments (EDs) commonly analyze cases of patients returning within 72 hours of initial ED discharge as...
-
Abstract Introduction In recent years, platelet-rich plasma (PRP) has emerged as a promising autologous biological treatment modality fo...
-
from EMS via xlomafota13 on Inoreader http://ift.tt/2sbML2K
-
from EMS via xlomafota13 on Inoreader http://ift.tt/2sbML2K
-
ORIGINAL ARTICLES Cone-beam computed tomography versus orthopantomography in sinus lift procedures: Two-dimensional versus three-dimension...
-
Haemovigilance programme of India: Comparative analysis of transfusion reactions reported over a 5-year period through two reporting formats...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου